Traditional thinking has it that corporate social responsibility doesn't help a company's bottom line. The truth is that not only can actively pursuing a policy of social responsibility cost a company nothing, but it can actually provide a boost for business.
The pharmaceutical industry is in crisis. Big, profitable products are losing their patent protection and generic producers are jumping in to take a growing share of the market. We look at how the big pharmas, and the smaller ones, can find a way through these troubled times.
European mobile operators are finally recovering from the hangover produced by the towering debt from the introduction of third-generation systems. Our annual survey found an industry bursting with challenges and opportunities for both incumbents and new entrants.
Companies are scrambling to find new and innovative products to enrich their customers' lives. Old inward-looking concepts of innovation no longer go far enough. Teaming up with external innovators offers new paths to outstanding product and process developments.
Why do some companies manage to move into high-end segments while others blunder? And why do some do extremely well at the bottom end of the market? The answer lies in product alignment, the key to keeping in close contact with your markets.